Key Points
- Mauro Ferrari sold 7,530 shares of Arrowhead on Dec. 26 at an average price of $70 for $527,100, reducing his ownership by 9.83% to 69,053 shares (worth ~ $4.83M).
- Ferrari also sold 8,750 shares on Nov. 28 at $56.39 (≈ $493,412), indicating multiple insider sales in recent months.
- Analysts maintain a consensus "Moderate Buy" with a $61.89 target; ARWR trades near its 12‑month high ($72.36) with 50‑day/200‑day averages of $52.96/$33.93 and a market cap of about $9.14B.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Mauro Ferrari sold 7,530 shares of the company's stock in a transaction on Friday, December 26th. The stock was sold at an average price of $70.00, for a total value of $527,100.00. Following the completion of the sale, the director directly owned 69,053 shares in the company, valued at approximately $4,833,710. The trade was a 9.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Mauro Ferrari also recently made the following trade(s):
- On Friday, November 28th, Mauro Ferrari sold 8,750 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $56.39, for a total value of $493,412.50.
Arrowhead Pharmaceuticals Stock Performance
Shares of ARWR stock opened at $67.25 on Wednesday. The company's fifty day moving average price is $52.96 and its 200-day moving average price is $33.93. The stock has a market cap of $9.14 billion, a PE ratio of -840.52 and a beta of 1.28. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $72.36.
Wall Street Analyst Weigh In
ARWR has been the subject of several analyst reports. HC Wainwright raised their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a "buy" rating in a research report on Tuesday, December 2nd. Bank of America increased their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a "buy" rating in a research note on Tuesday, December 9th. Morgan Stanley boosted their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 26th. Piper Sandler upped their price target on Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, December 17th. Finally, Chardan Capital reiterated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.89.
Check Out Our Latest Stock Report on ARWR
Hedge Funds Weigh In On Arrowhead Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. grew its position in Arrowhead Pharmaceuticals by 3.1% during the third quarter. PNC Financial Services Group Inc. now owns 10,924 shares of the biotechnology company's stock valued at $377,000 after buying an additional 326 shares during the period. State of Wyoming boosted its stake in shares of Arrowhead Pharmaceuticals by 5.6% during the 3rd quarter. State of Wyoming now owns 9,519 shares of the biotechnology company's stock worth $328,000 after acquiring an additional 504 shares during the last quarter. Arizona State Retirement System grew its position in shares of Arrowhead Pharmaceuticals by 1.9% during the 3rd quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company's stock valued at $1,126,000 after acquiring an additional 620 shares during the period. CWM LLC increased its stake in shares of Arrowhead Pharmaceuticals by 6.7% in the 3rd quarter. CWM LLC now owns 12,179 shares of the biotechnology company's stock worth $420,000 after purchasing an additional 764 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter worth $29,000. Hedge funds and other institutional investors own 62.61% of the company's stock.
About Arrowhead Pharmaceuticals
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company's pipeline includes multiple candidates in various stages of development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
